50 results about "Recombinant virus vaccine" patented technology

The invention discloses an adenovirus vector vaccine for preventing SARS-CoV-2 infection. The vaccine comprises a nucleic acid sequence as shown in SEQ ID NO: 1. According to a plurality of embodiments of the invention, the S protein nucleic acid sequence contained in the vaccine is easy to express in human cells, and generation of more S proteins can be induced, so the vaccine is expected to be used as a recombinant virus vaccine for preventing SARS-CoV-2 infection. According to a plurality of embodiments of the invention, the vaccine has good security.

The invention discloses a recombinant virus for expressing swine fever virus E2 gene, and a preparation method and application thereof. According to the preference of the codon, synthetic CSFV 2.1-type immunogenic gene E2 and 1.1-type E2 gene are respectively arranged in baculovirus pH and p10 promoters to be expressed so as to obtain a recombinant baculovirus (CCTCC NO:V201338). The exogenous gene expression level is enhanced. After being used for immunizing Japanese white rabbits and pigs, the subunit vaccine prepared by the E2 protein expressed by the recombinant baculovirus can induce the organism to generate specific immune reaction and protect the organism from the attack of the swine fever virus; and differential diagnoses can be utilized to distinguish the vaccine immunized animal from the wild virus-infected animal, thereby being beneficial to eradication and purification of the eradicate swine fever virus in the pig farm.

The invention provides a preparation method of a recombined new castle disease virus vaccine strain which expresses African swine fever virus p72 proteins and a recombined new castle disease virus vaccine strain. The method provided by the invention comprises the following steps: constructing a recombinant transcriptional plasmid which is inserted with a p72 gene of African swine fever virus (ASFV); constructing a transcriptional helper plasmid system; carrying out a contransfection for the transcriptional plasmids and the transcriptional helper plasmids into host cells BHK-21 which can be duplicated in new castle disease attenuate strains; and saving and obtaining the recombined virus stain. The vaccine strain for expressing the African swine fever virus p72 proteins provided by the invention has important preservation and strategy meaning in the aspect of animal epidemic disease prevention and control, and can be applied to the treatment and prevention of African swine fever virus.

The invention provides a preparation method of avian influenza virus HA gene recombinant adenovirus, which creatively comprises the following steps: carrying out a series of intermediate processes on plasmid pCAGGS, adenovirus shuttle plasmid pShuttle, adenovirus framework plasmid pAdEasy-1 and the like to obtain a gene expression plasmid and other intermediate products, and transfecting the obtained recombinant adenovirus plasmid with 293 cell; and carrying out immunohistochemical screening on the recombinant virus according to the adenovirus-infected cytopathy and specific cells. By using the CAG as the promoter to express the target gene, the method obviously enhances the expression level of the target gene. The hemagglutinin recombinant adenovirus for respectively expressing H5N1 and H9N2 subtype avian influenza viruses provides a virus model for development of the H5/H9 subtype avian influenza virus bivalent nucleic acid vaccine, and also lays the foundation for development of the AIV (avian influenza virus) adenovirus live vector vaccine.

The invention discloses a recombinant virus of a chimeric IBV H120 S1 gene ectodomain suitable for cell culture and a construction method and application thereof. The recombinant virus is constructed by the following steps of: replacing the S1 gene ectodomain segment of an IBV Beaudette strain with an S1 gene ectodomain segment of an IBV H120 strain to construct the recombinant virus; after successful virus rescue, passing from the Vero cell; collecting toxicity when the cell cytopathic effect area is over 90%; and repeatedly freezing and thawing for three times, and continuing passage to obtain the recombinant virus of a chimeric IBV H120 S1 gene ectodomain suitable for cell culture. The recombinant virus disclosed by the invention is used as a vaccine strain to immunize SPF chicken; after counteracting toxicity, the chicken flocks of an immunity group and a control group are continuously observed to discover that the recombinant virus disclosed by the invention can serve as a vaccine strain to provide good immunity protection to the inoculated chicken; and the recombinant virus is safe to various kinds of chicken and avoids side reaction.

The invention relates to a virus vaccine A-NDV-LX/14 for a newcastle disease, which is a recombinant of expressed genes VII F and HN, and the preservation number is CGMCCNO: 3844. After two weeks of the constructed virus A-NDV-LX/14 immunity test on chicken, the average potency of the serum HI is 27. After four days of eliminating toxic material with immune group LaSota, the virus isolation ratesof SPF chicken laryngotracheal and cloacal swab samples are 10 percent and 30 percent respectively, and the virus isolation rates of chicken laryngotracheal and cloacal swab samples are 40 percent and 20 percent respectively. After four days of eliminating toxic material with immune group V4, the virus isolation rates of SPF chicken laryngotracheal and cloacal swab samples are 30 percent and 10 percent respectively, and the virus isolation rates of chicken laryngotracheal and cloacal swab samples are 30 percent and 20 percent respectively. Compared with traditional vaccine, more effective immune protection can be provided by the recombinant virus vaccine.

The invention provides viral vectors, such as chimeric flavivirus vectors, including foreign peptides inserted into the target proteins of the vectors, methods of making and using these vectors, and compositions including the vectors.

The invention discloses an infectious laryngotracheitis recombinant virus strain for expressing a Newcastle disease virus F protein and establishment and the application of the strain and relates to the field of recombinant virus vaccines. Aiming at problems of recombinant virus establishment and the application of an exogenous immunogenic gene with a nonobligatory gene US9 locus of an ILTV (Infectious Laryngotracheitis Virus), the invention provides an infectious laryngotracheitis recombinant virus strain which is named as rILTV US9-NDV-F, the microorganism preservation number of the strain is CGMCC No.14738, and the virus strain is an infectious laryngotracheitis recombinant virus which is established by replacing a US9 gene of the infectious laryngotracheitis recombinant virus by the Newcastle disease virus F protein, establishing an acquirement deficiency US9 gene and by inserting an NDV-F (Newcastle Disease Virus-F Protein) expression box into a corresponding position of the gene,and is used for recombining the Newcastle disease virus F protein. The recombinant infectious laryngotracheitis recombinant virus strain disclosed by the invention is used for preparing vaccines forpreventing infectious laryngotracheitis and other chicken infectious diseases.

The invention provides a recombinant protein vaccine. The recombinant protein vaccine contains an epitope of EB virus antigen 1 (EBNA1) and an epitope of human herpes virus glycoprotein; fusion proteins can effectively activate a specific cell toxic T lymphocyte (CTL) reaction, directly restrain the expression EBNA1, and give play to treatment effects on EB virus-associated tumors; an immunosuppression path can be directly blocked through herpes virus glycoprotein, and the activity of regulatory T cells is improved. In this way, by means of the recombinant protein vaccine, EB virus infections and diseases related to the EB virus infections and tumors related to the EB virus infections can be prevented or treated in a multi-way manner more comprehensively. The invention further provides a recombinant expression vector containing genes for coding the recombinant protein vaccine and application of the recombinant protein vaccine.

The invention discloses a recombinant rabies virus carrying a deoptimized M gene and two G genes. Firstly, a reading frame part of the M gene is deoptimized, wherein the sequence after deoptimization is as shown in SEQ ID NO.2; secondly, a rabies virus HEP-Flury strain is taken as a skeleton, an M gene in the HEP-Flury is replaced by the deoptimized M gene, and an additional rabies virus G gene is inserted to obtain recombinant rabies virus pHEP-dG-Mmin plasmid carrying the deoptimized M gene and two G genes; finally, rescuing and screening are conducted to obtain a recombinant rabies virus strain rHEP-dG-Mmin. The recombinant virus has higher virus titer, and the cost of canine vaccine can be reduced. Under the condition of multiplicity of infection, G protein with higher level can be expressed, virus replication and transcription of each structural gene are increased, and the recombinant virus has the potential of serving as a rabies vaccine candidate strain.

The invention provides an application of living virus vector duck virus enteritis virus (DEV) attenuated vaccine vector in galliformes poultry. The DEV attenuated vaccine vector can be used for expressing relevant genes of the galliformes poultry pathogeny and can carry exogenous genes to be expressed in the galliformes poultry, and the protection for the pathogeny can be well induced in an immune animal body. Through the application of the recombinant duck virus enteritis virus vaccine strain (preservation serial number is CCTCC V201125, named as rDEVus78Ha-Re6) for expressing the avian influenza virus haemagglutinin (HA) genes and the recombinant duck virus enteritis virus vaccine strain (preservation serial number is CCTCC V201220, and named as rDEV F) for expressing newcastle disease virus gene F in chicken, the characteristics of the DEV attenuated vaccine vector can be proved.

The invention relates to an anti-HIV gene engineering recombinant virus and a preparation method thereof, and an anti-HIV gene engineering medicament. The anti-HIV gene engineering recombinant virus comprises a constant region of a human antibody, and a cluster of differentiation 4 (CD4) and a chemokine receptor 5 (CCR5) which are connected with the constant region. The preparation method for the anti-HIV gene engineering recombinant virus comprises the steps as follows: obtaining a heavy chain constant region gene of the human antibody, a light chain constant region gene of the human antibody, a CD4 gene and a CCR5 gene; constructing a virus vector shuttle plasmid comprising the four genes; co-transforming the shuttle plasmid and a virus auxiliary plasmid to generate a recombinant virus plasmid; and transferring the recombinant virus plasmid to a cell strain for culturing and purifying the virus. The recombinant virus has both the CD4 and CCR5 capable of specifically binding with the CD4 site and CCR5 site of an HIV virus, an obviously enforced specific binding effect, and the function of doubly preventing the HIV virus from infecting a host cell. The preparation method is simple and practical. The anti-HIV gene engineering medicament with the recombinant virus can effectively act on the HIV virus, and can further effectively prevent and treat the infection of the HIV virus.

The invention belongs to the technical field of biology and discloses swine influenza virus H1N1 subtype HA-1 protein recombinant suipoxvirus and a preparation method thereof. An HA1 gene is designed and synthesized according to the gene sequence of HA1 of an A/swine/Shanghai/1/2005(H1N 1) strain of the swine influenza virus, and the gene is cloned in a suipoxvirus vector pUSZ11 to obtain a transfer vector pUSZ11/H1. The recombinant virus is a positive clone obtained by infecting and transfecting PK15 cells with the suipoxvirus and the transfer vector pUSZ11/H1 and performing homologous recombination. The recombinant suipoxvirus can express HA1 protein stably, and after infection with the virus, the cytopathy becomes regular, the toxic effect of the breeding virus is stabilized at 107TCID50/mL, the breeding virus can effectively stimulate the immune protect reaction of organisms and can be used in the preparation of medicines for preventing and/or treating infection with swine influenza virus H1N1 subtype.

The invention relates to the technical fields of animal virology and genetic engineering and especially relates to a recombinant expression vector and a construction method thereof, a recombinant virus strain and an application thereof, a recombinant protein and a subunit vaccine. According to the invention, PCR amplification is successfully carried out for amplifying PRRSV-GP5 gene and PCV2-Cap gene and constructing a high-effective recombinant expression plasmid BacSC-Dual-GP5-Cap. In addition, the recombinant protein expressed by the recombinant virus strain is very high in product expression yield. The BacSC-Dual-GP5-Cap subunit vaccine product in the invention is safe to animal. An immune efficacy test result of the vaccine proves that PRRSV and PCV2 researched through a genetic engineering method have a strong immunogenicity. The subunit vaccine has a wide application prospect in the field of prevention and treatment of porcine reproductive and respiratory syndrome and porcine circovirus disease.

The invention discloses a primer, a kit and a detection method for detecting insect cell DNA residues. Through a method of using a real-time fluorescent quantitative PCR technology for qualitatively and quantitatively detecting the insect cell DNA residues and a PCR kit prepared according to the method, a quantitative limit of as low as 3fg/ul for detecting the insect cell DNA residues is realized; and in other words, the method has good sensitivity and specificity. The real-time fluorescent quantitative PCR method can be used for detecting recombinant protein or recombinant virus vaccines orgene therapy vectors produced by insect cells which are taken as expression host cells, such as recombinant adeno-associated viruses and the like, and can provide reliable quality detection data for research, development and safe production of the gene therapy vectors.

The invention discloses a construction method of a rabies virus G protein-goatpox virus recombinant vaccine. The construction method comprises the following steps of: 1, design of a recombinant virusvaccine construction model; 2, amplification of each gene and fusion amplification of each combined gene; 3, construction of various combined recombinant transfer vectors; 4, recombination of rabies virus G protein and goatpox virus and virus purification; 5, rabies virus G protein expression detection; and step 6, detection of the immune effect of a rabies virus G protein-goatpox recombinant virus vaccine strain. The vaccine constructed by the method can effectively prevent rabies of goat, has the characteristics of high production efficiency, simplicity, convenience and practicability, and is suitable for popularization and application.

The invention provides a recombinant sendai vector vaccine expressing HIVGag, construction method and application thereof. The vaccine is constructed based on an F gene defective sendai virus vector. The polynucleotide expressing HIVGag is properly modified and reconstructed so as to be able to realize high expression in eukaryotic cells without depending on regulatory protein Rev. The test result shows that the recombinant vector vaccine can express HIVGag correctly and can effectively induce in-vivo and in-vitro cellular immunity.